Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition

Current Drug Metabolism

Volumn 12, Issue 5, 2011, Pages 412-435

  Niwa, Toshiro ^a   Murayama, Norie ^a   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

CYP2D6; Genetic polymorphism; Inhibition constant; Meta analysis; Metabolic activity

Indexed keywords

AMITRIPTYLINE; ATOMOXETINE; BUDIPINE; BUFURALOL; CODEINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DEXTROMETHORPHAN; ENZYME VARIANT; FLUOXETINE; METHAMPHETAMINE; METOPROLOL; NORTRIMIPRAMINE; NORTRIPTYLINE; PAROXETINE; PROGESTERONE; QUININE; SPARTEINE; TRAMADOL; VENLAFAXINE;

AMINO ACID SUBSTITUTION; ARTICLE; COMPARATIVE STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVE SITE; ENZYME POLYMORPHISM; MICHAELIS MENTEN KINETICS; WILD TYPE;

ANIMALS; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MUTATION; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS;

EID: 79955690297     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795495286     Document Type: Article

References (38)

1. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34(1-2), 83-448. (Pubitemid 34311090)
2. Funae, Y., Kishimoto, W., Cho, T., Niwa, T., Hiroi, T. CYP2D in the brain. Drug Metab Pharmacokinet., 2003, 18(6), 337-349.
3. Maréchal, J.D., Kemp, C.A., Roberts, G.C., Paine, M.J., Wolf, C.R., Sutcliffe, M.J. Insights into drug metabolism by cytochromes P450 from modeling studies of CYP2D6-drug interactions. Br. J. Pharmacol., 2008, 153 Suppl 1, S82-S89. (Pubitemid 351340994)
4. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48(11), 689-723.
5. Human Cytochrome P450 (CYP) Allele Nomenclature Committee [online]). http://www.cypalleles.ki.se/ (Accessed July 31, 2010).
6. Niwa, T., Murayama, N., Emoto, C., Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 2008, 9(1), 20-33. (Pubitemid 351201667)
7. Niwa, T., Murayama, N., Yamazaki, H. Comparison of the contributions of cytochrome P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition. J. Health Sci., 2010 56(3), 239-256.
8. Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M., Hiratsuka, M. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos., 2008, 36(12), 2460-2467.
9. Hanioka, N., Okumura, Y., Saito, Y., Hichiya, H., Soyama, A., Saito, K., Ueno, K., Sawada, J., Narimatsu, S. Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem. Pharmacol., 2006, 71(9), 1386-1395.
10. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L.L., Ingelman-Sundberg M. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 2001, 11(5), 417-427. (Pubitemid 32656582)
11. Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences, J. Biol. Chem., 1992, 267, 83-90.
12. Niwa, T., Hiroi, T., Tsuzuki, D., Yamamoto, S., Narimatsu, S., Fukuda, T., Azuma, J., Funae, Y. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Mol. Brain Res., 2004, 129(1-2), 117-123. (Pubitemid 39304255)
13. Ramamoorthy, Y., Tyndale, R.F., Sellers, E.M. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics, 2001, 11(6), 477-487. (Pubitemid 32778226)
14. Shen, H., He, M.M., Liu, H., Wrighton, S.A., Wang, L., Guo, B., Li, C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 2007, 35(8), 1292-1300
15. Fukuda, T., Nishida, Y., Imaoka, S., Hiroi, T., Naohara, M., Funae, Y., Azuma, J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys., 2000, 380(2), 303-308. (Pubitemid 30659100)
16. Shiraishi, T., Hosokawa, M., Kobayashi, K., Tainaka, H., Yamaura, Y., Taguchi, M., Chiba, K. Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells. Drug Metab. Dispos., 2002, 30(11), 1201-1205. (Pubitemid 35265826)
17. van Waterschoot, R.A., Keizers, P.H., de Graaf, C., Vermeulen, N.P., Tschirret-Guth, R.A. Topological role of cytochrome P450 2D6 active site residues. Arch. Biochem. Biophys., 2006, 447(1), 53-58.
18. Flanagan, J.U., Maréchal, J.D., Ward, R., Kemp, C.A., McLaughlin, L.A., Sutcliffe, M.J., Roberts, G.C., Paine, M.J., Wolf, C.R.. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. Biochem. J., 2004, 380(Pt 2), 353-360. (Pubitemid 38788106)
19. Keizers, P.H., Lussenburg, B.M., de Graaf, C., Mentink, L.M., Vermeulen, N.P., Commandeur, J.N. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4- (aminomethyl)-coumarin metabolism. Biochem. Pharmacol., 2004, 68(11), 2263-2271. (Pubitemid 39446153)
20. Masuda, K., Tamagake, K., Okuda, Y., Torigoe, F., Tsuzuki, D., Isobe, T., Hichiya, H., Hanioka, N., Yamamoto, S., Narimatsu, S. Change in enantioselectivity in bufuralol 1-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. Chirality, 2005, 17(1), 37-43. (Pubitemid 39665573)
21. Guengerich, F.P., Hanna, I.H., Martin, M.V., Gillam, E.M.. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry, 2003, 42(5), 1245-1253. (Pubitemid 36184065)
22. Paine, M.J., McLaughlin, L.A., Flanagan, J.U., Kemp, C.A., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J. Biol. Chem., 2003, 278(6), 4021-4027. (Pubitemid 36801135)
23. Lussenburg, B.M., Keizers, P.H., de Graaf, C., Hidestrand, M., Ingelman-Sundberg, M., Vermeulen, N.P., Commandeur, J.N. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochem. Pharmacol., 2005, 70(8), 1253-1261. (Pubitemid 41317519)
24. Zanger, U.M., Fischer, J., Raimundo, S., Stüven, T., Evert, B.O., Schwab, M., Eichelbaum, M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 2001, 11(7), 573-585. (Pubitemid 32953583)
25. Masuda, K., Tamagake, K., Katsu, T., Torigoe, F., Saito, K., Hanioka, N., Yamano, S., Yamamoto, S., Narimatsu, S. Roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6. Chirality, 2006, 18(3), 167-176 (Pubitemid 43334160)
26. Tsuzuki, D., Takemi, C., Yamamoto, S., Tamagake, K., Imaoka, S., Funae, Y., Kataoka, H., Shinoda, S., Narimatsu, S. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics, 2001, 11(8), 709-718. (Pubitemid 33078241)
27. Tsuzuki, D., Hichiya, H., Okuda, Y., Yamamoto, S., Tamagake, K., Shinoda, S., Narimatsu, S. Alteration in catalytic properties of human CYP2D6 caused by substitution of glycine-42 with arginine, lysine and glutamic acid. Drug Metab. Pharmacokinet., 2003, 18(1), 79-85.
28. Yu, A., Kneller, B.M., Rettie, A.E., Haining, R.L. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther., 2002, 303(3), 1291-1300. (Pubitemid 35424416)
29. Allorge, D., Bréant, D., Harlow, J., Chowdry, J., Lo-Guidice, J.M., Chevalier, D., Cauffiez, C., Lhermitte, M., Blaney, F.E., Tucker, G.T., Broly, F., Ellis, S.W. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins, 2005, 59(2), 339-346. (Pubitemid 40471571)
30. Ellis, S.W., Hayhurst, G.P., Lightfoot, T., Smith, G., Harlow, J., Rowland-Yeo, K., Larsson, C., Mahling, J., Lim, C.K., Wolf, C.R., Blackburn, M.G., Lennard, M.S., Tucker, G.T. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6. Biochem. J., 2000, 345, 565-571. (Pubitemid 30099086)
31. Hayhurst, G.P., Harlow, J., Chowdry, J., Gross, E., Hilton, E., Lennard, M.S., Tucker, G.T., Ellis, S.W. Influence of phenylalanine- 481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem. J., 2001, 355(Pt 2), 373-379. (Pubitemid 32397796)
32. Matsunaga, M., Yamazaki, H., Kiyotani, K., Iwano, S., Saruwatari, J., Nakagawa, K., Soyama, A., Ozawa, S., Sawada, J., Kashiyama, E., Kinoshita, M., Kamataki, T. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Drug Metab. Dispos. 2009, 37(4), 699-701.
33. Keizers, P.H., Van Dijk, B.R., De Graaf, C., Van Vugt-Lussenburg, B.M., Vermeulen, N.P., Commandeur, J.N. Metabolism of Nsubstituted 7-methoxy-4-(aminomethyl) -coumarins by cytochrome P450 2D6 mutants and the indication of additional substrate interaction points. Xenobiotica, 2006, 36(9),763-771. (Pubitemid 44395479)
34. Rowland, P., Blaney, F.E., Smyth, M.G., Jones, J.J., Leydon, V.R., Oxbrow, A.K., Lewis, C.J., Tennant, M.G., Modi, S., Eggleston, D.S., Chenery, R.J., Bridges, A.M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 2006, 281(11), 7614-7622 (Pubitemid 43847532)
35. Margolis, J.M., O'Donnell, J.P., Mankowski, D.C., Ekins, S., Obach, R.S. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000, 28(10), 1187-1191.
36. McLaughlin, L.A., Paine, M.J., Kemp, C.A., Maréchal, J.D., Flanagan, J.U., Ward, C.J., Sutcliffe, M.J., Roberts, G.C., Wolf, C.R. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J. Biol. Chem., 2005, 280(46), 38617-38624. (Pubitemid 43853763)
37. Ellis, S.W., Hayhurst, G.P., Smith, G., Lightfoot, T., Wong, M.M., Simula, A.P., Ackland, M.J., Sternberg, M.J., Lennard, M.S., Tucker, G.T., Wolf, C.R. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem., 1995, 270(49), 29055-29058.
38. Niwa, T., Okada, K., Hiroi, T., Imaoka, S., Narimatsu, S., Funae, Y. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol. Pharm. Bull., 2008, 31(3), 348-351. (Pubitemid 351442125)